Dynavax

3D rendering of SARS-CoV-2 virus particles
Biotech

Dynavax pays Vaxart $30M for oral COVID-19 vaccine program

The deal allows Dynavax to see phase 2b data before placing a bigger bet on the program.
Nick Paul Taylor Nov 6, 2025 5:50am
Cartoon of business people competing in a tug of war

VC firm fights to end Dynavax's 'empire-building' strategy

Feb 19, 2025 2:22pm
vials vaccine research vaccines factory manufacturing

Dynavax drops Tdap vaccine after mulling ph. 1 data, competition

Nov 8, 2024 9:31am
cancer cell surrounded by killer T cells

Novel cancer vaccines look beyond T cells to better fight tumors

May 27, 2022 2:00pm